Domainex and Pharmidex Announce Drug Discovery Services Alliance
News Jan 29, 2010
Domainex Ltd and Pharmidex announced the formation of a strategic alliance, combining their expertise and technologies to provide the market with an integrated, high-quality drug discovery services platform.
The joint service offering will amalgamate Domainex’s LeadBuilder technology for hit-finding, as well as its highly-experienced medicinal chemistry team, with Pharmidex’s renowned expertise and in vitro and in vivo capabilities in drug metabolism and pharmacokinetics (DMPK).
Concordant with the established track records of both partners, the alliance will have a particular emphasis on tackling the most challenging of scientific problems, including novel or “difficult” drug targets.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019